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ABSTRACT
Triple negative breast cancer patients have a poor course of disease not least 
because of limited treatment options however immunotherapy by targeting the PD-1/
PD-L1 checkpoint system is a promising strategy to improve the outcome. Here we 
systematically investigated the expression of PD-1 on tumor infiltrating lymphocytes 
and PD-L1 on both tumor and infiltrated immune cells. Moreover, the PD-L1 gene 
status in tumor cells was assessed. 
103 tissue microarray samples derived from triple negative breast cancer 
specimens were immunohistochemically stained against PD-1 and PD-L1. Dual marker 
fluorescence in-situ hybridization was applied to the PD-L1 gene and centromere 
region of chromosome 9. The disease free and overall survival rates were determined 
as a function of the PD-1/PD-L1 status.
A slight gain of the PD-L1 gene region was found in 55% of all samples but 
an elevated PD-L1/cen9 ratio was rather rare (7%). An increased gene dose is not 
associated with an enhanced protein expression and the PD-L1 expression only 
weakly correlates with the amount of immune cell infiltration. Instead, we found an 
association of PD-L1 expression on tumor and immune cells, respectively. Notably, 
the PD-1 expression on immune cells is associated with a favorable disease free and 
overall survival. PD-1 expression indicates an enhanced immunological anti-tumor 
activity and represents a favorable prognostic impact. A deeper understanding of 
factors that affect the regulation and function of the PD-1/PD-L1 system is required 
to establish predictive variables and to utilize the system for therapeutic intervention 
of triple negative breast cancer patients. 
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INTRODUCTION
Triple negative breast cancers (TNBC) account for 
10–17% of all breast cancers (BC), tend to grow more 
aggressively than other subtypes, show relatively early 
recurrence and intrinsically have poor prognosis [1]. 
Due to the lack of estrogen receptor (ER), progesterone 
receptor (PR), and HER2 receptor expression therapeutic 
options are limited to appropriate cytotoxic treatments. 
However, due to its enhanced immunogenicity TNBC 
represent a sub-entity that is apparently predestined for 
an immunotherapeutic intervention, e.g., an anti-immune 
checkpoint treatment.
Immunotherapy research is trying to overcome the 
cancer’s ability to resist the immunological tumor defense 
and to stimulate or to reactivate mechanisms that result 
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in regaining immunological effectiveness against cancer. 
To this end different strategies are being developed, 
amongst them a specific targeting of molecules that are 
involved in curbing immune cells. Programmed cell death 
protein 1 (PD-1) expressed on (activated) T-cells and 
the corresponding programmed death ligand 1 (PD-L1)
expressed on immune and tumor cells represent a prominent 
inhibitory immune checkpoint system that has been 
demonstrated to play a major role for example in malignant 
melanoma [2, 3] and squamous non-small cell lung cancer 
[4, 5]. An immune checkpoint treatment has already been 
FDA approved for these entities. In contrast, the immune 
checkpoint targeting in BC patients is being evaluated but 
not yet part of the approved therapeutic portfolio [6].
Due to its higher genetic instability, an enhanced 
mutational load, and the appearance of neoantigens 
PD-L1 expression is more frequently found in HER2-
positive and triple negative BCs than in other BC sub-
entities (e.g., the luminal cohorts) [7]. Moreover, PD-
L1 expression has been associated with the degree of 
tumor infiltrating lymphocytes (TILs) [8–10]. However, 
systematic analyses addressing the PD-1/PD-L1 system 
in BC are rare. First data from the KEYNOTE-012 
(NCT01848834) study revealed a clinical activity of an 
anti-PD-1 IgG4, namely pembrolizumab [10]. More 
specifically, in 27 PD-L1-positive (pre-treated) TNBC 
patients, the application of pembrolizumab achieved an 
overall response rate of 18.5%, although only patients with 
PD-L1-pos. tumors (cut off: ≥ 1% PD-L1-pos cells) were 
included. Other clinical trials especially addressing TNBC 
and HER2-pos. patients are ongoing [6, 11, 12]. The 
GeparNuevo trial (NCT02685059), for instance, evaluates 
the therapeutic efficacy of the PD-L1 antibody MED14736 
(AstraZeneca) in combination with a taxane/anthracycline 
based cytotoxic treatment of TNBC (https://clinicaltrials.
gov/ct2/show/NCT02685059). Interestingly, even patients 
with PD-L1-negative scored tumors seem to benefit from 
an anti-PD-L1 treatment. Even though it is known that 
PD-L1 expression can be triggered as response to a T-cell 
attack, the underlying molecular / cellular mechanisms 
contributing to the treatment response require elucidation. 
It appears plausible, however, that an efficient inhibition of 
an immunological tumor defense by PD-L1-positive tumor 
cells requires interaction with PD-1-positive lymphocytes. 
Thus, a systematic assessment of both parts of the PD-1/
PD-L1 system on tumor cells and TILs will shed light on 
the tumor tissue related immune status and might reveal a 
valuable prognostic or predictive impact.
Here we scored the amount of TILs in 103 TNBC 
samples and immunohistochemically evaluated the 
expression of PD-L1 on tumor cells and lymphocytes. In 
addition we analyzed the PD-1 expression on TILs and 
quantified the PD-L1 gene copy number in tumor cell 
nuclei by fluorescence-in-situ-hybridization (FISH). We 
associated and correlated these parameters to each other 
and retrospectively analyzed the overall and progression 
free survival (OS, PFS) of TNBC patients as a function of 
PD-1 and PD-L1. Overall, we found a favorable outcome of 
TNBC patients with PD-1 positive TILs compared to those 
patients who had tumors with lymphocytes expressing low 
levels or no PD-1.
RESULTS
An increased PD-L1 gene copy number or PD-L1/
cen9 hybridization ratio is rare
To evaluate the range of variation in normal tissue 
and to estimate the threshold for pathological gene 
amplification, we analyzed PD-L1 and cen9 gen copy 
numbers in 18 benign mammary tissues derived from 
breast cancer reduction surgeries (Figure 1A). In those 
tissues we found the PD-L1 gene copy number within the 
range of 1.79–2.27 (SD = 0.12, mean = 2.03). The mean 
of cen9 hybridization was 1.99 (SD = 0.11) and ranged 
between 1.77 and 2.21. Accordingly, the mean of the 
PD-L1/cen9 ratio in healthy tissue was 1.02 (SD 
= 0.04) and was within the range of 0.94–1.10. 
These thresholds were applied to define copy 
number alterations in breast cancer tissues. We 
found 59/103 (57%) samples with increased 
(> 2.27) PD-L1 gene copy numbers whereas 44/103 (43%) 
were below the amplification threshold (Figure 1B). 
Off note, 5 patients were even below the average 
mean of healthy donors and are considered to carry 
a PD-L1 gene loss (copy number < 1.8). Most often, a 
slightly increased PD-L1 gene copy number occurs 
simultaneously with a likewise moderately increased 
cen9 copy number which results in a PD-L1/cen9 ratio 
within the normal range (Figure 1C). In only seven 
samples we revealed a significantly enhanced PD-L1/
cen9 ratio (≥ 2.03) which is supposed to represent a 
moderate but real gene amplification (Figure 1B–1D). 
A strong association between the PD-L1 and cen9 gene 
copy number was validated by the calculated Pearson’s 
correlation coefficient (r = 0.652; p < 0.001; Figure 1D). 
A PD-L1 gene copy gain, a loss, and a simultaneously 
increased PD-L1 and cen9 copy number are exemplarily 
shown in Supplementary Figure 1A, I–III, respectively. 
No correlation between the PD-L1 gene copy number and 
the OS (p = 0.87) or PFS (p = 0.62) could be revealed 
(Supplementary Figure 1B and 1C).
An increased PD-L1 gene copy number in tumor 
cells is not associated with an enhanced PD-L1 
protein expression
PD-L1 positive tumor cells were found in 55/97 
(57%) of all specimens. However, in 37/55 of all positive 
samples the frequency of positive cells was below 10%. 
Notably, no correlation was found between the PD-L1 
gene copy number and PD-L1 expression (r = 0.053; 
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p = 0.607; n = 97; Figure 2A) and not between the PD-
L1/cen9 ratio and PD-L1 positive tumor cells (r = 0.087; 
p = 0.397; n = 97; Figure 2B). PD-L1 positive TILs 
were found in 71/98 (72%) of all cases. Five samples 
of immunochemically stained and PD-L1 gene/cen9-
hybridized tissue specimens are exemplarily shown in 
Supplementary Figure 2.
PD-L1 expression on tumor cells is associated 
with PDL-1 expression on immune cells but 
without significant impact on OS or PFS
We calculated a (weak) correlation between PD-
L1 expression on tumor cells and on TILs (p < 0.01; 
Spearman-Rho factor = 0.455; Table 1). Nevertheless, 
PD-L1 expression on tumor cells does not significantly 
affect the OS (Figure 3A; p = 0.74) or the PFS (Figure 3B; 
p = 0.59) of the patients. Complementary, the 
PD-L1 expression on TILs does also not correlate with OS 
(p = 0.31) or PFS (p = 0.14) as shown in Figure 3C and 3D. 
In addition, the TIL score does not correlate with the PD-
L1 expression on tumor cells (Spearman-Rho = 0.227; 
data not shown). Moreover, the TIL score (Supplementary 
Figure 3) is not significantly associated with an increased 
OS (p = 0.17) or PFS (p = 0.13). Only nine samples with 
low infiltration (Score 1 = 1–9 TIL/HPF) but 43 tissues 
scored 2 (10–49 TIL/HPF) and 50 scored 3 (>50 TIL/HPF) 
were identified. Overall, 93/102 (91%) of all samples 
showed high (Score 2) or a very high (Score 3) immune 
cell infiltration. Therefore, only a trend towards a better 
outcome of disease for Score 3 cases (compared to Score 
1/2 cases) could be revealed (Supplementary Figure 3).
The presence of PD-1 positive TILs correlates 
with the presence of PD-L1 tumor cells and is 
associated with an improved OS and PFS
Despite the fact that the TIL score could not be 
correlated to PD-L1 expression nor to the patient’s OS 
and PFS the presence of PD-1 positive TILs favorably 
affects the outcome of disease: On the on hand we found a 
direct correlation of PD-1 expression on TILs and PD-L1 
Figure 1: PD-L1 gene amplification (FISH) in TNBC patients. (A) determination of PD-L1, centromere copy number 
and ratio in benign breast tissue (mean +/– SD; n = 18). Threshold for abnormal gene amplification/loss were estimated by the 
calculation: mean +/– 2× SD. (B) 103 TNBC were analyzed using the cut off 2.27 PD-L1 gene/1 cell determined in (A) and grouped in 
PD-L1 increased (n = 59 (57%)) and PD-L1 normal/decreased (n = 44 (43%)) samples. (C) TNBC patients were separated into PD-L1 gene 
amplified (> 2 (ratio); n = 7 (7%)) and not altered (< 2 (ratio); n = 96 (93%)). (D) Correlation between PD-L1 gene and centromere copy 
number per cell were determined using Pearson’s correlation coefficient (r = 0.652; p < 0.001; n = 103). Red symbols in (B, C and D) refer 
to 7 samples with PD-L1/cen9 ratio >2.0.  
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Figure 2: PD-L1 gene amplification and PD-L1 protein expression in TNBC. (A) There is no correlation between PD-L1 gene 
copy number (r = 0.053; p = 0.607; n = 97) (B) nor a correlation between PD-L1/cen9 ratio (r = 0.087; p = 0.397; n = 97) and the PD-L1 
expression (%) on tumor cells. Correlation was measured using the Pearson correlation coefficient.
Figure 3: PD-L1 expression on TILs or tumor cells and its correlation to OS and PFS in TNBC patients. Kaplan–Meier 
overall survival (OS; (A) p = 0.87) and progression free survival (PFS; (B) p = 0.62) curves in patients with different PD-L1 expression 
on tumor cells are displayed. There were also no correlation detectable between overall survival (OS; (C) p = 0.31) and progression free 
survival (PFS; (D) p = 0.14) in patients with different PD-L1 expression on TIL. The p values were calculated using the log-rank test 
(Mantel-Cox).
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expression on tumor cells (Figure 4A; r = 0.469 (p < 0.001), 
n = 99) and between PD-1 and PD-L1 expression on TILs 
(Figure 4B; r = 0.493 (p < 0.001); n = 101). On the other 
hand, and even more importantly, the PD-1 expression 
on TILs has a favorable impact on the OS (Figure 5A; 
p = 0.06) and especially on the PFS (Figure 5B; p = 0.045). 
The PD-1 expression turned out as the strongest prognostic 
marker that determines the outcome of disease.
DISCUSSION
Aim of this study was to evaluate the PD-1/PD-L1 
status on tumor and immune cells in TNBC specimens 
both on the genomic and protein level. Data sets were 
correlated mutually and to the outcome of disease. 
We assessed the PD-L1 gene and cen9 copy 
numbers in tumor cells of 103 TNBC tissues by dual 
marker FISH and interrelated the cytogenetic data to the 
respective PD-L1 expression. We found 59/103 (57%) 
events with a rather moderate increase of PD-L1 gene 
copy numbers. Not more than 7/103 (7%) specimens 
showed an elevated PD-L1 gene copy number only (i.e., 
no increased cen9 numbers) which results in a (slightly) 
enhanced PD-L1/cen9 ratio. In contrast, 96/103 samples 
(93%), including those with moderately enhanced PD-
L1 gene copy numbers, come without an increase of the 
PD-L1/cen9 ratio which suggests the absence of PD-L1 
gene amplification in these cases. Since the PD-L1 gene 
region is located very much distal on the short arm of 
chromosome 9 (i.e., 9p24.1) and far away from the cen9 
region a common amplification of both regions can be 
excluded in samples that show both moderately enhanced 
PD-L1 and cen9 copy numbers. Instead, the correlation 
of simultaneously elevated PD-L1 gene and cen9 copy 
numbers (r = 0.65), which does not result in an increased 
PD-L1/cen9 ratio, indicates the presence of (low grade) 
polysomy 9. Moreover, the missing correlation between 
PD-L1 gene copy numbers and PD-L1 expression on 
tumor cells suggests that the PD-L1 gene dose does not 
determine the degree of protein expression. In other 
words an enhanced PD-L1 protein expression was 
found independently from the PD-L1 gene copy number 
and the PD-L1/cen9 ratio. Unlike as, for example, the 
expression of the HER2 receptor protein, which (in BC) 
is strongly determined by the her2 gene copy number/ 
gene amplification, the PD-L1 expression seems not to 
be chromosomally determined. This is consistent with 
other studies in which only a weak correlation of PD-L1 
Figure 4: PD-1 and PD-L1 expression on tumor and immune cells. (A) Correlation between PD-L1 expression on tumor cells 
and PD-1 expression on TIL is displayed (person rho = 0.469; p < 0.001; n = 99). (B) The correlation between PD-L1 and PD-1 expression 
on TIL are displayed as number and % in groups belonging to both scores (Spearman-Rho = Spearma n = 0.493 (p < 0.001, n = 101).
Table 1: PD-L1 expression on tumor cells and immune cells in TNBC
PD-L1 IHC score (tumor cells)
0 1 2 3 total
P
D
-L
1 
IH
C
 
Sc
or
e 
(T
IL
s)
0 n (%) 25 (24.3%) 7 (6.8%) 1 (1.0%) 0 (0.0%) 33 (32.0%)
1 n (%) 16 (15.5%) 16 (15.5%) 4 (3.9%) 7 (6.8%) 43 (41.7%)
2 n (%) 6 (5.8%) 9 (8.7%) 7 (6.8%) 5 (4.9%) 27 (26.2%)
total n (%) 47 (45.6%) 32 (31.1%) 12 (11.7%) 12 (11.7%) 103 (100.0%)
The correlation between PD-L1 expression on TIL and PD-L1 expression on tumor cells are displayed as number and % in 
groups belonging to both scores. The overall correlation between both characteristics were measured using the Spearman 
correlation coefficient (Spearman-Rho = 0.455; p < 0.01).
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transcripts and no correlation of PD-L1 protein content 
with PD-L1 gene copy number aberrations were reported 
[13, 14]. Moreover, the PD-L1 expression seems to be not 
directly triggered by the presence of lymphoid immune 
cells. Instead, there is evidence suggesting that PD-L1 
expression is rather regulated by a variety of alternative 
mechanisms, amongst them the activity of signaling 
pathways, transcriptional factors, epigenetic factors, and a 
number of microRNAs [15]. PD-L1 has been described to 
be multifactorial and in particular dynamically regulated. 
For example, PD-L1 negative tumor cells might permit 
T-cells to invade into the tumor tissue. However, PD-
L1 expression can be induced by IFNγ released by these 
activated T- or NK cells. Vice versa, a PD-L1 expression 
by tumor cells can impede (further) T-cell infiltration and 
INFγ release that might entail reduced PD-L1 expression. 
Thus, the PD-L1 phenotype is most likely not stable but 
affected by multiple factors and is rather independent from 
the inherent PD-L1 gene copy number.
Within the cohort of TNBC patients subjected to 
this study PD-L1 does not significantly affect the course 
and outcome of disease neither when expressed on tumor 
cells nor on immune cells. Even though an association 
between PD-L1 expression and longer survival has been 
described elsewhere for non-gynecological malignancies 
e.g., metastatic melanoma [16] as well as merkel cell 
[17] and colorectal carcinomas [18]. The PD-L1 related 
survival data of BC patients are greatly inconsistent [19]. 
A number of studies performed on basal-like or TNBC 
reported a positive correlation between PD-L1 expression 
and a favorable prognosis [13, 20, 21]. However, a reverse 
correlation between PD-L1 expression and prognosis has 
been also described [22–24]. Overall, it appears evident 
that the regulation of PD-L1 expression does not underlie 
a simple unidimensional factor but is regulated in a rather 
complex and multifactorial manner. A number of potential 
factors contributing to the regulation of PD-L1 expression 
on tumor cells are discussed in more detail elsewhere [16]. 
For example, the presence of PD-L1 positive (tumor) 
cells is considered as an indicator of immunosuppression 
(caused by an immune cell attack) but might also imply 
a tumor response to endogenous inflammatory activity 
[16, 15]. As indicated by a preclinical study [26] and a 
very recent analysis on 58 patients with early (and mainly 
hormone receptor positive) BC patients in a neoadjuvant 
setting [27] the PD-L1 expression on tumor and stromal 
cells can change (either increase or decrease) upon 
cytotoxic treatments. However, the same study reported 
that - similar to our findings - neither the initial PD-
L1 expression nor the modified expression in residual 
compared to primary tumors had an effect on patient’s 
outcome [27]. 
We found that the PD-L1 expressions on tumor 
and immune cells do correlate, which is in good 
agreement with other reports on non-small cell lung 
cancer [28] and even BC [29]. The finding suggest that 
the immunosuppressive environment is determined by 
both immune and tumor cells. More importantly, we 
revealed a correlation of tumor cell related PD-L1 and 
immune cell related PD-1 expression, which indicates a 
tumor-immune-cell interaction and an antigen-induced 
and TILs mediated anti-tumor immune pressure. An 
induction of the PD-1/PD-L1 checkpoint system and 
associated pathways by activated CD8+ and INFγ has 
been previously observed in a melanoma based murine 
model [30]. Although incompletely effective, recruitment 
of TILs to the tumor site (e. g., by chemotactic attractants) 
might have induced a partial antitumor activity that 
can explain our observation. More specifically, PD-1 
expression on antigen-experienced CD8+ T-cells, which 
had contact to PD-L1-pos. tumor or immune cells, might 
represent a T-cell phenotype characterized by impaired 
Figure 5: PD-1 expression on TILs and its relevance on OS and PFS. Kaplan–Meier overall survival (A) p = 0.06) and progression 
free survival (B) p = 0.045) curves in patients with different PD-1 expression are displayed. The p values were calculated using the log-rank 
test (Mantel-Cox).
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effector function and a persistent expression of inhibitory 
receptors, a phenomenon, which has been termed “T-cell 
exhaustion” [31]. The presence of formerly or currently 
activated PD-1 positive immune cells is supposed to 
reflect some degree of immunological tumor defense 
which in turn might favorably affect the course of disease. 
Indeed, we revealed a prolonged OS as a function of PD-1 
positivity. More precisely, the higher the TIL associated 
PD-1 score the better the OS. This finding substantiates the 
interpretation that an antigen-induced antitumor immune 
pressure raises a recruitment of immune cells to the tumor 
site that results in a partially successful antitumor defense.
The presence of TILs in particular in HER2-positive 
and TNBC samples has been repeatedly associated with 
a favorable prognosis [32, 33] and, not less importantly, 
with an improved response to neoadjuvant cytotoxic 
[34, 35] and target specific [24, 36, 37] tumor treatments. 
However, the infiltrated immune cells have been rarely 
sub-classified or phenotyped. Bottai et al. found PD-1 (and 
LAG-3) positive TILs in 15% of TNBCs and an association 
of PD-1 expression with the presence of CD8+ cytotoxic 
T-cells [33]. Here we report that not only the presence 
of TILs in general but in particular PD-1 positive TILs 
(conceivably T-cells) have a significant favorable impact 
on the outcome of TNBC disease. A number of studies 
undertaken on BC and other tumor entities (e.g., head and 
neck cancer) concord with this finding [38], whereas others 
do not [39–41]. Considering, that the immunohistochemical 
assessment of PD-1 on TILs is inherently a “snap shot” at 
a given time, PD-1 positivity might either represent the 
active state of lymphocytes (when analyzed relatively 
early during the carcinogenesis and progression) or reflect 
an already expired lymphocyte activity (exhaustion upon 
interaction with PD-L1). Taking a temporal regulation into 
account might explain discrepancies within reports. Overall, 
the prognostic impact of PD-1 expression on TILs (in BC 
and other malignancies) remains uncertain and subject of 
complex temporal and multifactorial regulation. Extended 
analyses are required that include additional parameters 
involved in this regulation.
We could not reveal a correlation of an increasing 
amount of TILs (expressed by the TIL score ranging from 
0 to 3) with the PFS or OS. This is probably due to the fact 
that most of the tumor samples came with a rather enhanced 
immune cell infiltration (i.e., 93/103 (90%) samples had 
an infiltration score of 2 or 3). Tissue specimens without 
the presence of TILs (Score 0) were not observed at all. 
In this study we did not differentiate lymphocyte subsets. 
However, PD-1 expression can basically be found on 
T-, NK-, and B-cells, but also on monocytes and even 
regulatory T-cells (Tregs). It has been reported that PD-1-pos. 
Tregs represent impaired activity [42]. A reduced activity of 
Tregs can cause an increased activity of effector T-cells and 
consequently stimulate the systemic immune response. 
A tumor cell associated PD-L1 and Treg associated PD-1 
interaction, which would impair a Treg mediated inhibition 
of e. g., cytotoxic T-cells, could explain the favorable 
impact of PD-1 which entails an improved outcome of 
disease [25]. Although, our data did not reveal a direct 
correlation between the tumor cell associated PD-L1 
expression and disease outcome a correlation between the 
PD-1 and PD-L1 expression became obvious which might 
support the afore outlined interpretation.
A drawback of our study might be the use of 
TMAs (instead of total tissue specimens) since immune 
cell infiltration can be heterogeneous and vary amongst 
different tissue areas. Consequently, the size of specimens 
that undergoes the investigation potentially plays a role 
for proper evaluation of immune cell infiltration and 
the estimation of PD-1 and PD-L1 expression [25]. One 
might expect, for example, that PD-L1 positive tumor 
cells can predominantly be found close to the TILs rather 
than in non-infiltrated areas. However, no relationship 
has yet been demonstrated between the tissue size 
and PD-L1 expression nor between time since sample 
collection and IHC staining [43] and the use of TMAs for 
immunochemical PD-1/PD-L1 analyses is not uncommon 
[41]. Here the selection of a tissue area for inclusion 
into this study was performed under supervision of a 
pathologist who screened the available tissue totally and 
thereby made sure not to oversee potential immune cell 
infiltration. Based on this procedure we found 90% of all 
samples to be TIL positive, though to a different extent. 
Overall, the prognostic value of both PD-L1 and 
PD-1 expression in TNBC (and probably other taxonomic 
BC entities) remains uncertain and requires further 
investigation. Notwithstanding, data supporting either 
a favorable or an adverse effect of the PD-1/PD-L1 
system on the course of disease should not necessarily be 
contradictory since different effects of PD-1/PD-L1 might 
be elicited by the environment and the type of immune cell 
that express this receptor and its ligand. Hence, it is rather 
unlikely that the assessment of PD-L1 only (expressed on 
tumor cells) will decisively facilitate a patient stratification 
in respect of eligibility for a checkpoint treatment. Instead, 
the data heterogeneity amongst a great number of studies 
suggests that multifactorial analyses are required to 
understand the impact of PD-1/PD-L1 positive cells with 
tumor tissues on immunological defense, tumor growth 
and progression and finally the course and outcome of 
disease. Further studies that comprise not only the overall-
evaluation of TILs and the degree of PD-L1 expression on 
tumor and immune cells but also include the differential 
analysis of PD-1 expression on immune cell subpopulations 
(i.e., NK-, dendritic, CD4- and CD8-positive T-cells, and 
monocytes) will specify and thus considerably enhance 
the diagnostic and prognostic significance of immune cell 
analyses [24]. Moreover, additional biomarkers such as the 
TIL formation, the presence of neoantigens presented by 
HLA molecules or soluble factors in the microenvironment 
could be informative. Only differential / multiplex analyses 
of the regulation of PD-1 and PD-L1 expression on tumor 
and immune cells will assure any prognostic and predictive 
impact. 
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MATERIALS AND METHODS
TNBC patient database
103 TNBC tissue samples were derived upon 
surgery and were recruited between the years 2004 to 
2015. 90.5% of those samples, which were derived from 
cytotoxically treated patients, were taken at the non-
pretreated stage (Table 2). The triple negative status 
was (immuno-)histochemically determined based on 
the estrogen/progesterone receptor, Ki67, and Her2-
receptor status and the grading, and if applicable by FISH, 
determined by pathological diagnostics at the University 
of Regensburg. Clinico-pathological parameters were 
documented by the institute of pathology and the breast 
cancer center of the university cancer center Regensburg 
(Table 2). Clinical follow up was correlated with the data 
from the Tumor Centre Regensburg a population-based 
Table 2: Basic demographic data of 103 evaluable TNBC cases (BCT = breast conserving therapy)
Clinico-pathological parameter (n) (%)
Tumor stage
I 24 23.3
II 52 50.4
III 12 11.7
IV 7 6.8
unknown 8 7.8
Histologic subtype
invasive ductal 90 87.3
invasive lobular 0 0
medullary 12 11.7
mucinous 1 1
Grading
1 1 1
2 19 18.4
3 77 74.8
unknown 6 5.8
Mean age at diagnosis: 53.4y
premenopausal 43 41.7
postmenopausal 54 52.4
unknown 6 5.8
Surgery
mastectomie 41 39.8
BCT 62 60.2
Radiation
yes 70 68
no 29 28.2
unknown 4 3.8
Chemotherapy 
a: yes 84 81.6
b: adjuvant 76 90.5 (of a)
c: neoadjuvant 8 9.5 (of b) 
d: no 11 10.7
e: unknown 8 7.8
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regional cancer registry covering a population of more 
than 2.2 million people including Upper Palatinate and 
Lower Bavaria. The documentation comprises individual 
patient data, information on primary diagnosis, treatment 
regimens, course of disease, and the complete follow-up. 
Benign control tissues were taken from healthy women 
who underwent breast reduction. 
Fluorescence in-situ hybridization and imaging
FISH was performed as described recently [13]. In 
brief 3–4 µm thick deparaffinized TMA specimens were 
pretreated in 98°C 0.01N Na-Citrate buffer for 30 min, 
incubated with pepsin (ZytoVision Ltd., Bremerhaven, 
Germany) for 5 min at 37°C, and washed with Millipore 
water followed by ethanol dehydration (70, 80, and 100%). 
Subsequently, ten µl of the original probe were added on 
each specimen and slides were covered by a cover glass 
and fixogum rubber cement. After a denaturation step 
(5 minutes at 73°C), slides were incubated over night at 
37°C. Finally, the cover glass was removed, the samples 
were washed, and 4′,6-diamidino-2-phenylindole (DAPI) 
nuclear counter staining was added according to the 
manufacturer’s instruction.
Fluorescence in situ hybridization was performed 
using the directly labeled PDCD1LG2/cen9 dual color 
probe (ZytoVision GmbH, Bremerhaven, Germany). The 
PDCD1LG2 specific probes were labeled with SpectrumGreen 
and the cen9 specific probe with SpectrumOrange. 
PDCD1LG2 hybridization spots reflect the PD-L1 gene copy 
number whereas the cen 9 spots are considered to reflect the 
number of chromosome 9 within a cell nucleus. 
Sealed slides were imaged with an AxioImager Z1 
fluorescence microscope (Zeiss, Oberkochen, Germany) 
equipped with specific filter sets for DAPI fluorescence 
(excitation 360 ± 20 nm, emission 460–25 nm), 
SpectrumGreen (excitation 480 ± 15 nm, emission 535 
± 20 nm), SpectrumOrange (excitation 538 ± 10 nm, 
emission 575 ± 15 nm). Hybridization signals in 25 non-
overlapping cell nuclei per specimen were quantified 
by two independent observers, and count values were 
averaged. If necessary, brightfield microscopy was used 
to verify the presence of either malign or benign breast 
tissue in the visual field. Analyzes were performed using 
AxioImager-Z1 (Zeiss) and the hybridization signals of 
50 non-overlapped nuclei were manually counted on 
single cell basis. Results are presented as PD-L1 gene 
signals per one cell and calculated as FISH ratio (PD-L1 
gene signals/chromosome 9 signals).
Tissue embedding and manufacture of tissue 
microarrays
All specimens were acquired from the tissue archive 
of the Institute of Pathology, University of Regensburg 
(Germany). The embedding procedure was performed as 
described elsewhere [44]. Immediately after surgery, the 
breast tissues were transferred into the formalin fixative 
(4% formaldehyde, 1% sodium phosphate; SG Planung, 
Holzkirchen, Germany). The total fixation time was 
between 12 h (min.) and 36 h (max.). The specimens 
were then subjected to automated dehydration and 
paraffin immersion. Tissue dehydration was performed 
by subjecting the tissues to a series of ascending ethanol 
concentrations (70% for 30 min, 70% for 60 min, 96% 
for 60 min, 96% for 50 min, 100% for 50 min, and 100% 
for 90 min), and was completed by incubation in 100% 
xylene (2 × 50 min). Finally, the tissues were embedded 
in paraffin by the use of a Shandon Hypercenter XP 
(2 × 30 min; 2 × 60 min).
Tissue microarrays (TMAs) were generated as 
described previously [45] and were used for PD-L1 
immunohistochemistry and PD-L1/cen9 FISH analyses. 
In brief, for each tumor a representative tumor section 
was selected from a hematoxylin and eosin (H&E)-stained 
section of the donor block. The relevant tissue section was 
identified by a pathologist based on tissue architecture, 
morphology and HER2-IHC. Core cylinders with a diameter 
of 1.5 mm each were punched from this area and deposited 
into a recipient paraffin block; 4 µm TMA sections were 
mounted on charged slides (SuperFrost Plus; Menzel, 
Braunschweig, Germany) and used for FISH analysis. H&E-
stained TMA sections were used for reference histology.
PD-L1 immunohistochemistry and bright field 
microscopy 
1.5 µm paraffin sections were prepared from the 
embedded tissue blocks. Specimens were deparaffinized 
and pretreated by microwave heating for 30 min at 
320 W in 0.1 M citrate buffer adjusted to pH 7.3. The 
immunostaining was automatically performed on a 
Ventana Nexes autostainer (Ventana, Tucson, USA) 
by using the streptavidin– biotin peroxidase complex 
method and 3,3′-diaminobenzidine (DAB) as chromogen. 
The autostainer was programmed based on the instructions 
given by the iView DAB detection kit (Ventana). The 
mouse monoclonal anti-PD-1 antibody NAT105 (ab52578) 
and the rabbit monoclonal anti-PD-L1 28–8 (ab205921) 
were used (both abcam, Cambrindge, MA, USA). The 
specimens were microscopically analyzed using a Zeiss 
Axiovert 200 instrument (Zeiss). The degree of immmune 
cell infiltration and the frequency of positive immune/tumor 
cells were scored by percentage or by number of cells/
high power fields (HPF) and translated into a score system 
ranging that covers the scores 0, 1, 2, and 3 (Tables 3–6). 
Statistical analyses
Survival curves were estimated using the Kaplan–
Meier method, and the log-rank test was used to test 
for differences between the groups. To calculate the 
Oncotarget6210www.impactjournals.com/oncotarget
association between parameters, Pearson or Spearman 
correlation coefficient analyses were applied. All reported 
P-values were two-sided. P values less than 0.05 were 
considered significant. All statistical analyses were 
performed using R version 3.3.3 (The R Foundation 
for Statistical Computing) or GraphPad Prism (Ver. 6, 
GraphPad Software, La Jolla, CA, USA).
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